

Rec'd

PTO 20 APR 2005

40/532152  
PG 16 B03 104655

INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP1 0BQQ

12 DEC 2003

WIPO

PCT


**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Andrew Gurney*

Dated

17 November 2003

THE PATENT OFFICE

The  
Patent  
Office

31 OCT 2002

310012 E75915-1 D02814  
P01/00 0 00-0225282.3

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

100873

2. Patent application number

(The Patent Office will fill in this part)

0225282.3

31 OCT 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB  
S-151 85 Sodertalje  
Sweden

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

ASSAY

5. Name of your agent (if you have one)

Allen F. Giles

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited  
Global Intellectual Property  
Mereside, Alderley Park  
Macclesfield  
Cheshire SK10 4TG

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (2))

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 7

Claim(s) 2

Abstract

Drawing(s) 1 & 1

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Authorised Signatory

30/10/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer C Bennett - 01625 230148

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

ASSAY

This invention a cellular proliferation assay for a compound acting through erbB-2 wherein the cell is responsive to ligand stimulated cell proliferation.

5 New therapeutic approaches to cancer are needed. The receptor tyrosine kinases are of particular importance in the transmission of mitogenic signals that initiate cellular replication. These large glycoproteins, which span the plasma membrane of the cell possess an extracellular binding domain for their specific ligands (such as Epidermal Growth Factor (EGF) for the EGF Receptor). Binding of ligand results in the activation of the receptor's  
10 kinase enzymatic activity that is encoded by the intracellular portion of the receptor. This activity phosphorylates key tyrosine amino acids in target proteins, resulting in the transduction of proliferative signals across the plasma membrane of the cell.

It is known that the erbB family of receptor tyrosine kinases, which include EGFR, erbB-2, erbB-3 and erbB-4, are frequently involved in driving the proliferation and survival of  
15 tumour cells (reviewed in Olayioye *et al.*, EMBO J., 2000, 19, 3159). One mechanism in which this can be accomplished is by overexpression of the receptor at the protein level, generally as a result of gene amplification. This has been observed in many common human cancers (reviewed in Klapper *et al.*, Adv. Cancer Res., 2000, 77, 25).

As a consequence of the mis-regulation of one or more of these receptors (in particular  
20 erbB-2), it is widely believed that many tumours become clinically more aggressive and so correlate with a poorer prognosis for the patient (Brabender *et al.*, Clin. Cancer Res., 2001, 7, 1850; Ross *et al.*, Cancer Investigation, 2001, 19, 554, Yu *et al.*, Bioessays, 2000, 22.7, 673). In addition to these clinical findings, a wealth of pre-clinical information suggests that the erbB family of receptor tyrosine kinases are involved in cellular transformation. This  
25 includes the observations that many tumour cell lines overexpress one or more of the erbB receptors and that EGFR or erbB-2 when transfected into non-tumour cells have the ability to transform these cells. This tumourigenic potential has been further verified as transgenic mice that overexpress erbB-2 spontaneously develop tumours in the mammary gland. In addition to this, a number of pre-clinical studies have demonstrated that anti-proliferative  
30 effects can be induced by knocking out one or more erbB activities by small molecule inhibitors, dominant negatives or inhibitory antibodies (reviewed in Mendelsohn *et al.*, Oncogene, 2000, 19, 6550). Thus it has been recognised that inhibitors of these receptor tyrosine kinases should be of value as a selective inhibitor of the proliferation of mammalian

cancer cells (Yaish *et al.* Science, 1988, 242, 933, Kolibaba *et al.*, Biochimica et Biophysica Acta, 1997, 133, F217-F248; Al-Obeidi *et al.*, 2000, Oncogene, 19, 5690-5701; Mendelsohn *et al.*, 2000, Oncogene, 19, 6550-6565). In addition to this pre-clinical data, findings using inhibitory antibodies against EGFR and erbB-2 (c-225 and trastuzumab respectively) have  
5 proven to be beneficial in the clinic for the treatment of selected solid tumours (reviewed in Mendelsohn *et al.*, 2000, Oncogene, 19, 6550-6565).

The search for new drugs frequently involves a "screening cascade". This cascade often starts with an in vitro assay and ultimately extends into in vivo assays. More meaningful data is often obtained from in vivo assays, but at the sacrifice of throughput such  
10 that it is not usually practicable to put a large number of compounds through an in vivo assay. It is usual to screen compounds in higher throughput assays and take forward only the more promising leads to the next assay in the screening cascade for optimal efficiency. A highly desirable assay which fits between in vitro and in vivo assays is a cell proliferation assay.

It is known that non-neoplastic epithelial cells like H16N-2 can respond in a  
15 proliferative manner to stimulation with either EGF or heregulin (Ram, G.R. and Ethier, S.P.(1996) Cell Growth and Differentiation, 7, 551-561). However there is presently no known cell based assay for compounds acting through erbB-2 that uses a ligand stimulated proliferation assay to measure cytostatic and cytotoxic potency. There is a need for such an assay because of the desire to distinguish between a compound that specifically inhibits cell  
20 proliferation through through erbB-2 (real hits) and those compounds inhibiting cell growth through non-specific toxicity caused by the compound (false hits).

One aspect of the invention provides a cellular proliferation assay for a compound acting through erbB-2 which comprises:

- i) a cell comprising erbB-2 and erbB-3 and said cell is responsive to ligand stimulated  
25 cell proliferation under conditions suitable for cell proliferation;
- ii) a first ligand which is a ligand for erbB-3 capable of inducing proliferation by the cell;
- iii) mixing i) and ii) in the presence and absence of compound;
- iv) measuring whether the compound has any effect on reducing cell proliferation.

The cell may be recombinant or non-recombinant but if recombinant they should be  
30 engineered lines to express the receptors at low/normal levels to gain ligand responsiveness. "Mixing" simple means that the components are brought together into a homogeneous mixture, continuous mixing is not required. Measurement of cell proliferation may be by any suitable means; Example 1 below exemplifies one suitable method.

Preferably the cellular proliferation assay comprises the addition of a control wherein the compound is tested in parallel in the absence of ligand to detect non-specific cell toxicity. This has the advantage of being able to distinguish between a compound that specifically inhibits cell proliferation through through erbB-2 (real hits) and those compounds inhibiting  
5 cell growth through non-specific toxicity caused by the compound (false hits).

Preferably the cellular proliferation assay comprises the addition of a second assay which is an assay for measuring whether the compound has activity through EGFR which comprises:

- i) a cell comprising erbB-2, erbB-3 and EGFR under conditions suitable for cell  
10 proliferation;
- ii) a second ligand which is a ligand for EGFR capable of inducing proliferation by the cell;
- iii) mixing i) and ii) in the presence and absence of compound;
- iv) measuring whether the compound has any effect on reducing cell proliferation.

15 This is advantageous because it enables the ability to profile the activity of compounds potentially acting through erbB-2 and EGFR. Note that for some pharmaceutical purposes it is desirable to have compounds that act through both targets (dual specificity). It is also contemplated that combinations of individual compounds may also be tested.

Preferably the cellular proliferation assay provided herein endogenously expresses  
20 EGFR and/or erbB-2 and/or erbB-3, more preferably EGFR, erbB-2 and erbB-3.

"Endogenously" means that the cell has not been recombinantly engineered to express a particular receptor.

Preferably the first ligand is 'a member of the neuregulin family of ligands, preferably heregulin. Most preferably the first ligand is heregulin  $\beta$ 1.

25 Preferably the second ligand is EGF.

In one embodiment a preferred cell is an immortalised normal epithelial H16N-2 cell.

In another embodiment a preferred cell is a MCF-7 cell. MCF-7 cells are available from the ATCC. MCF-7 cells are neoplastic however they have a 'normal' erbB receptor expression profile.

"Cell proliferation" means increase in cell number through a process of cell division. Suitable conditions for cell proliferation are known in the art through provision of appropriate media, incubation conditions etc. Example 1 below provides one set of conditions for a particular cell line.

5 "Ligand stimulated cell proliferation" means that cell proliferation is driven through the activation of endogenous receptor by the addition of an exogenous ligand.

"Reduces cell proliferation" means that there is a statistically significant (95 % confidence, preferably 99% confidence) reduction in cell number compared with control

"Control" means a reference measurement against which a test result is compared to  
10 reduce experimental errors.

"A compound acting through erbB-2" means that proliferation is reduced as a consequence of the inhibition of an activity associated with erbB-2. The invention is particularly useful for detecting compounds which are kinase inhibitors, for example ATP mimetics. Note that the kinase domain of erbB-3 bears little homology to the kinase domain  
15 of the other members of the family that have high homology. Even if this is a kinase domain, it is non-functional as it has been shown to be devoid of any significant activity. Therefore it is very unlikely for such kinase inhibitor compounds detected by this assay compounds to work through erbB-3. It is contemplated that the assay is also useful for detecting compounds that block the binding of heregulin to erbB3 or the binding of erbB3 to erbB2.

20 "Compound has activity through EGFR" means that proliferation is reduced as a consequence of the inhibition of an activity associated with EGFR. The invention is particularly useful for detecting compounds which are kinase inhibitors, for example ATP mimetics. It is contemplated that the assay is also useful for detecting compounds that block the binding of EGF to EGFR or binding of erbB3 to EGFR or EGFR dimerisation.

25 "Tested in parallel" means assayed sufficiently close in time to act as a control. For the avoidance of doubt, exactness in time is not required.

"Non-specific cell toxicity" means poisonous effects of a compound exerted through the inhibition of cellular mechanisms or processes other than those which the agent is intended to interrupt.

30 "erbB-2" is defined as Epidermal Growth Factor Receptor 2.

"erbB-3" is defined as Epidermal Growth Factor Receptor 3.

"EGF" is defined as Epidermal Growth Factor Receptor 1.

"Heregulin  $\beta 1$ " is a member of the neuregulin family of ligands that preferentially promote the formation of erbB-2/erbB-3 heterodimers.

Note that erbB family of receptor tyrosine kinases, which include EGFR, erbB-2, erbB-3 and erbB-4, are reviewed in Olayioye et al., EMBO J., 2000, 19, 3159.

5 "Ligand binding to erbB-3 which in turn activates erbB-2 driven cell proliferation" means, without wishing to be bound by theoretical considerations, that since no cognate ligand is known for erbB-2, this receptor can be activated indirectly by ligand binding to erbB-3 which then forms a heterodimer with erbB-2, the intracellular kinase domain thereof then being activated to start mitogenic signalling mechanisms in the cell. Compounds which  
10 bind to and inhibit the kinase domain are detected by the claimed invention.

"Immortalised normal epithelial H16N-2 cells" have been described by Band, V. and Sager, R. Tumour progression in breast cancer. In: J. S. Rhim and A. Dritschilo (eds.), *Neoplastic Transformation in human Cell Culture*, pp 169-178. Clifton, NJ: Humana Press, 1991) and are obtainable from the Dana-Farber Cancer Institute, 44 Binney Street, Boston,  
15 Massachusetts 02115, USA. Literature references which involve use of H16N-2 cells include the following: Ram (1996) *Molecular Carcinogenesis* **15**: 227-238; Ram (1996) *Cell Growth and Differentiation* **7**:551-561; Ram (1995) *J. Cellular Physiology* **163**: 589-596; Berquin (2001) **20**: 4089-4028; Ram (2000) *J. Cellular Physiology* **183**: 301-313 and Ram (2000) *Cell Growth and Differentiation* **11**:173-183.

20 "Ligand for erbB-3" means a member of the neuregulin family of ligands that preferentially promotes the formation of erbB-2/erbB-3 heterodimers; heregulin  $\beta 1$  is preferred.

"Ligand for EGFR" means TGF $\alpha$  or EGF; EGF is preferred.

The invention will now be illustrated in the following non-limiting Examples in  
25 which:

Figure 1 shows the effect of compound 2 on heregulin driven cell proliferation

Figure 2 shows the effect of compound 2 on EGF driven cell proliferation

Figure 3 shows the effect of compound 2 on cells in the absence of ligand to detect non-specific toxicity.



**Example 1****H16N-2 cell proliferation assay**

This assay measures the ability of a test compound to inhibit heregulin  $\beta 1$  or EGF driven proliferation of H16N-2 cells. These non-neoplastic epithelial cells respond in a proliferative manner to stimulation with either EGF or heregulin  $\beta 1$  (Ram, G.R. and Ethier, S.P. (1996) *Cell Growth and Differentiation*, 7, 551-561) were isolated from human mammary tissue (Band, V. and Sager, R. Tumour progression in breast cancer. In: J. S. Rhim and A. Dritschilo (eds.), *Neoplastic Transformation in human Cell Culture*, pp 169-178. Clifton, NJ: Humana Press, 1991) and were obtained from the Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115.

H16N-2 cells were routinely cultured in culture medium (a 1:1 mix of Gibco F12 and Ham's  $\alpha$ MEM media containing 1 % foetal calf serum, 10mM HEPES, 1 $\mu$ g/ml Insulin, 12.5ng/ml EGF, 2.8 $\mu$ M Hydrocortisone, 2nM Estradiol 5 $\mu$ M Ascorbic Acid, 10 $\mu$ g/ml Transferrin, 0.1mM Phosphoethanolamine, 15nM Sodium Selenite, 2mM Glutamine, 10nM Tri-iodo-thyrone, 35 $\mu$ g/ml Bovine pituitary Extract and 0.1mM Ethanolamine) at 37°C in a 7.5% CO<sub>2</sub> air incubator. Cells were harvested from the stock flasks using Trypsin/ethylaminediaminetetraacetic acid (EDTA). Cell density was measured using a haemocytometer and viability was calculated using trypan blue solution before being seeded at a density of 1.0x10<sup>3</sup> cells per well of a 96 well plate in the above media at 37°C in 7.5% CO<sub>2</sub> and allowed to settle for 72 hours.

Following this, the cells were starved of serum for 24 hours upon the addition of starvation medium (a 1:1 mix of Gibco F12 and Ham's  $\alpha$ MEM media containing, 10mM HEPES, 2nM Estradiol, 5 $\mu$ M Ascorbic Acid, 10 $\mu$ g/ml Transferrin, 0.1mM Phosphoethanolamine, 15nM Sodium Selenite, 2mM Glutamine, and 0.1mM Ethanolamine) and incubated at 37°C in 7.5% CO<sub>2</sub>. The cells were then treated with or without compound at a range of concentrations in dimethylsulfoxide (DMSO) (1% final) for two hours before the addition of exogenous ligand (at a final concentration of 100ng/ml of heregulin  $\beta 1$  or 5ng/ml of EGF) and incubation with both ligand and compound for 4 days at 37°C in 7.5% CO<sub>2</sub>. Following the incubation period, cell numbers were determined by removal of the media by aspiration and incubating with 50 $\mu$ l of 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (stock 5mg/ml) for 2 hours. MTT solution was then removed by aspiration, allowed to air dry and the cells dissolved upon the addition of 100 $\mu$ l of DMSO.

Absorbance of the solubilised cells was read at 540nm to quantify cell biomass.

Inhibition of proliferation was expressed as an IC<sub>50</sub> value. This was determined by calculation of the concentration of compound that was required to give 50% inhibition of proliferation. The range of proliferation was calculated from the positive (vehicle plus ligand) and negative (vehicle minus ligand) control values.

### Example 2

#### Test results obtained using the cell proliferation assay of Example 1

Typical test data obtained for erbB-2 selective compounds, EGFR selective compounds and a compound with activity at both receptors is shown below along with a control (no ligand) for measurement of non-specific toxicity.

Compound	Heregulin (Average)		EGF (Average)		Basal (Average)	
	IC50	SD	IC50	SD	IC50	SD
erbB-2 selectives:						
1	0.054	0.050	0.945	0.078	3.954	3.320
2	0.155	0.005	>1	0.000	2.353	0.427
3	0.432	0.165	>1	0.000	4.848	1.746
dual specificity:						
4	0.011	0.012	0.109	0.036	0.445	0.395
EGFR selectives:						
5	0.009	0.010	0.047	0.067	0.371	0.195

"SD" means standard deviation.

The plots, which were used to generate the summary data above, are shown in Figures 1-3.




**Claims:**

1. A cellular proliferation assay for a compound acting through erbB-2 which comprises:
  - i) a cell comprising erbB-2 and erbB-3 and which is responsive to ligand
- 5 stimulated cell proliferation under conditions suitable for cell proliferation;
  - ii) a first ligand which is a ligand for erbB-3 capable of inducing proliferation by the cell;
  - iii) mixing i) and ii) in the presence and absence of compound;
  - iv) measuring whether the compound has any effect on reducing cell proliferation.
- 10 2. A cellular proliferation assay according to claim 1 comprising the addition of a control wherein the compound is tested in parallel in the absence of ligand to detect non-specific cell toxicity.
3. A cellular proliferation assay according to claim 1 or 2 comprising the addition of a second assay which is an assay for measuring whether the compound has activity through
- 15 EGFR which comprises:
  - i) a cell comprising erbB-2, erbB-3 and EGFR under conditions suitable for cell proliferation;
  - ii) a second ligand which is a ligand for EGFR capable of inducing proliferation by the cell;
  - 20 iii) mixing i) and ii) in the presence and absence of compound;
  - iv) measuring whether the compound has any effect on reducing cell proliferation.
4. A cellular proliferation assay according to any preceding claim wherein the cell endogenously expresses EGFR and/or erbB-2 and/or erbB-3.
5. A cellular proliferation assay according to claim 4 wherein the cell endogenously
- 25 expresses EGFR, erbB-2 and erbB-3.
6. A cellular proliferation assay according to any preceding claim wherein the first ligand is a heregulin.
7. A cellular proliferation assay according to claim 6 wherein the first ligand is heregulin  $\beta$ 1.
- 30 8. A cellular proliferation assay according to any one of claims 3-7 wherein the second ligand is EGF.
9. A cellular proliferation assay according to any preceding claim wherein the cell is an immortalised normal epithelial H16N-2 cell.

100873

- 9 -

10. A cellular proliferation assay according to any one of claims 1-8 wherein the cell is a MCF-7 cell.

**Figure 1: HRG driven proliferation:****Figure 2: EGF driven proliferation:****Figure 3: Basal/no ligand proliferation:**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**